During the corresponding time, Verrica Pharmaceuticals Inc saw a revenue deteriorated by -53.85 % year on year, sequentially revenue grew by 16.7 %. While revenue at the Verrica Pharmaceuticals Inc 's corporate clients
Verrica Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company provides YCANTH (VP-102) to pediatric dermatologists, high decile dermatologists, pediatricians, and primary care healthcare providers in the United States. Physicians access YCANTH through retail independent or specialty pharmacies via a "white bag" service or on a buy and bill basis through wholesale distribution partners. In the fourth quarter of 2025, the company launched YCANTH-Rx, a non-dispensing pharmacy designed to streamline prescription processing regardless of patient insurance. The market access team has secured coverage for YCANTH for approximately 250 million lives in the U.S., including commercial, Medicaid, and Managed Medicaid channels. The company sources naturally-sourced cantharidin from a supplier in the People’s Republic of China. This supplier was previously under an exclusivity agreement with Funing County Development Brucea Javanica Professional Cooperatives; however, the agreement no longer applies due to unmet purchase minimums. As of December 31, 2025, the company maintained significant inventories of finished drug product applicators and raw materials. Contract manufacturers and packaging vendors are based in the U.S. and are FDA-registered.
Verrica Pharmaceuticals Expands Distribution Network with Walgreens Specialty Pharmacy PartnershipWEST CHESTER, Pa., Jan. 03, 2024 - Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leading dermatology therapeutics company focused on developing medications for skin diseases requiring medical interventions, announced its latest endeavor to widen its distribution network. The company has entered into a partnership agreement with Walgreen Co. (Walgreens) to distribute its revolutionary skin therapy, YCANTH, through its specialty pharmacy. This collaboration marks an exciting milestone for Verrica as it propels its mission to provide effective and accessible treatment options for patients suffering from dermatolog...
Verrica Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company provides YCANTH (VP-102) to pediatric dermatologists, high decile dermatologists, pediatricians, and primary care healthcare providers in the United States. Physicians access YCANTH through retail independent or specialty pharmacies via a "white bag" service or on a buy and bill basis through wholesale distribution partners. In the fourth quarter of 2025, the company launched YCANTH-Rx, a non-dispensing pharmacy designed to streamline prescription processing regardless of patient insurance. The market access team has secured coverage for YCANTH for approximately 250 million lives in the U.S., including commercial, Medicaid, and Managed Medicaid channels. The company sources naturally-sourced cantharidin from a supplier in the People’s Republic of China. This supplier was previously under an exclusivity agreement with Funing County Development Brucea Javanica Professional Cooperatives; however, the agreement no longer applies due to unmet purchase minimums. As of December 31, 2025, the company maintained significant inventories of finished drug product applicators and raw materials. Contract manufacturers and packaging vendors are based in the U.S. and are FDA-registered.
Sources:
Verrica Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Verrica Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Verrica Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
160.06 %